Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com
Julie Refardt, MD, PhD: Current Hyponatremia Clinical Interventions Sufficient
Refardt discussed findings from the largest hyponatremia trial ever conducted, including 2174 participants across 9 European centers.
Read More
Dapagliflozin Lowers Risk of Decline in Late-Stage Kidney Disease
The dapagliflozin group had an average eGFR rate of -2.24 mL/min/1.73 m2 compared to -3.67 mL/min/1.73 m2 in the control group after about 1.5 years of follow-up.
Semaglutide Shows Benefit in CKD and Type 2 Diabetes Across Kidney Disease Severities
Participants receiving semaglutide had an overall hazard ratio of 0.76 in the composite primary outcome of kidney failure, serious eGFR decline, or death compared to placebo.
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Herrington shared the carryover effects observed in the post-trial follow-up of the phase 3 EMPA-KIDNEY trial.
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Yee discussed how the data show a benefit in this hard-to-treat population, which was not seen in the heterogeneous FSGS group.
Ladan Zand, MD: Obinutuzumab a Promising Option for Refractory, Primary FSGS
Zand discussed interim 12-month findings from an open-label, phase 2 trial currently ongoing for patients with refractory primary focal segmental glomerulosclerosis.
Empagliflozin Benefits on Kidney Disease Progression, Death Continue for 1 Year Post-Discontinuation
After discontinuing therapy, treated participants still had an overall 13% reduction in the risk of kidney disease progression or cardiovascular death.
Obinutuzumab Reduced Proteinuria, Improved eGFR in FSGS
Overall, 8 of 20 patients had complete or partial remission of their FSGS.
Sibeprenlimab Meaningfully Reduces uPCR in Adults With IgA Nephropathy
The data, which will be presented at a later time, may enable regulatory submission for accelerated approval to the FDA.
Multimorbidity Screening Reduced Hospitalizations in Patients With Rheumatic Diseases
Patients exposed to screening were also more likely to receive vaccinations and consult a cardiologist and/or a pneumologist.
Ahmad Masri, MD, MS: Establishing Proof-of-Concept of Gene Editing in ATTR-CM
Masri previewed data to be presented at the AHA 2024 Scientific Sessions and shared his excitement for the ongoing phase 3 trial of NTLA-2001.
New Presentation of Ustekinumab Biosimilar Approved for Crohn’s, Ulcerative Colitis
Ustekinumab-aekn is set to enter the US market no later than February 21, 2025, as per a settlement and license agreement between Janssen, Teva, and Alvotech.
Methotrexate May Lower Vaccine Response in Patients With RA
Investigators analyzed antibody response after 2 SARS-CoV-2 vaccinations.
Oral Semaglutide Reduces MACE Risk in People With Type 2 Diabetes and CVD
Novo Nordisk will present more detailed data in 2025 and plans to file for an expanded label for Rybelsus for this population.
Tart Cherry Supplementation Shows No Effect on Hyperuricemia Responses
The treatment did seem to blunt the glycemic response and influence some inflammatory cytokines.
EP-104IAR Phase 2 Data Shows Potential for Knee Osteoarthritis Pain
The ER fluticasone propionate intra-articular injection significantly reduced pain compared with control for up to 14 weeks.
Study Identifies Gut Microbiome Makeup, Diversity Differences in People With Fibromyalgia
The study also identified a tendency for more prevalent human herpesvirus 6B in people with FM than in those without.
High Genetic Gout Risk Associated With Increased Risk of CVD
Adherence to a preventative, favorable lifestyle significantly reduced CVD risk in participants with high and low genetic risk.
Appropriate Skin Prick Tests Can Limit Risk of Oral Food Challenges in Pediatric Allergies
Findings from the study also continued to support a positive Ara h 2-sIgE as the single most important predictor of peanut allergy.
Tonix Pharma Submits NDA for TNX-102 SL, Potential Fibromyalgia Medication
Two pivotal phase 3 studies previously met their endpoints of significantly reducting daily pain compared with placebo.
Research Elucidates MASLD Association With Cardiovascular Disease
Compared with older nomenclature, MASLD was significantly associated with severe artery calcification.
Burden, Inequality, Complications of MASLD Growing in Prevalence
The burden of LC-MASLD has significantly increased, especially in economically disadvantaged countries.
New Administration Options Approved for Bimekizumab for Psoriasis, PsA
The new administration options allow a single-injection option for patients that require a 320 mg dose.
Guselkumab Yields Durable Improvements in Psoriatic Arthritis
Of patients randomized to guselkumab Q8W, 93% to 99% maintained minimally clinically important improvements in joint disease through 1 year.
Post-COVID-19 Musculoskeletal Pain Often Fulfills Fibromyalgia Criteria
Over 70% of participants with MSK pain after COVID-19 fulfilled ACR fibromyalgia criteria in new research.
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Calabrese discussed considerations for patients with rheumatic disease diagnosed with COVID-19 and the virus’s role in promoting inflammation.
FDA Approves Marstacimab-hncq (Hympavzi) for Hemophilia A or B Without Inhibitors
The anti-TFPI significantly reduced ABR compared to routine prophylaxis treatment in the phase 3 BASIS trial.
Highly Beneficial Antipsychotics Underutilized in People With Schizophrenia
Second-generation long-acting injectables were particularly underutilized, and especially among older patients.
Stronger Safety Considerations Needed for Lumateprone Use, Especially for Women
Being female and having bipolar II disorder were independent risk factors for serious AEs in a new study.
Radiomics Model Distinguishes Gout Flares, May Improve Clinical Decision Making
A comprehensive model of clinical and radiomic features was more accurate in distinguishing flares than either model alone.